Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Medicinas Complementares
Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Endocr J ; 67(1): 73-80, 2020 Jan 28.
Artigo em Inglês | MEDLINE | ID: mdl-31611477

RESUMO

Those who smoke nicotine-based cigarettes have elevated plasma levels of ghrelin, a hormone secreted from the stomach. Ghrelin has various physiological functions and has recently been shown to be involved in regulating biological rhythms. Therefore, in this study, in order to clarify the significance of the plasma ghrelin increase in smokers, we sought to clarify how nicotine and ghrelin affect the expression dynamics of clock genes using a mouse model. A single dose of nicotine administered intraperitoneally increased plasma ghrelin concentrations transiently, whereas continuous administration of nicotine with an osmotic minipump did not induce any change in the plasma ghrelin concentration. Single administration of nicotine resulted in a transient increase in ghrelin gene expression in the pancreas but not in the stomach, which is the major producer of ghrelin. In addition, in the pancreas, the expression of clock genes was also increased temporarily. Therefore, in order to clarify the interaction between nicotine-induced ghrelin gene expression and clock gene expression in the pancreas, nicotine was administered to ghrelin gene-deficient mice. Administration of nicotine to ghrelin-gene deficient mice increased clock gene expression in the pancreas. However, upon nicotine administration to mice pretreated with octanoate to upregulate ghrelin activity, expression levels of nicotine-inducible clock genes in the pancreas were virtually the same as those in mice not administered nicotine. Thus, our findings indicate that pancreatic ghrelin may suppress nicotine-induced clock gene expression in the pancreas.


Assuntos
Peptídeos e Proteínas de Sinalização do Ritmo Circadiano/efeitos dos fármacos , Grelina/efeitos dos fármacos , Hipotálamo/efeitos dos fármacos , Nicotina/farmacologia , Agonistas Nicotínicos/farmacologia , Pâncreas/efeitos dos fármacos , RNA Mensageiro/efeitos dos fármacos , Estômago/efeitos dos fármacos , Fatores de Transcrição ARNTL/efeitos dos fármacos , Fatores de Transcrição ARNTL/genética , Animais , Proteínas CLOCK/efeitos dos fármacos , Proteínas CLOCK/genética , Caprilatos/farmacologia , Peptídeos e Proteínas de Sinalização do Ritmo Circadiano/genética , Criptocromos/efeitos dos fármacos , Criptocromos/genética , Mucosa Gástrica/efeitos dos fármacos , Mucosa Gástrica/metabolismo , Regulação da Expressão Gênica , Grelina/genética , Grelina/metabolismo , Transportador de Glucose Tipo 2/efeitos dos fármacos , Transportador de Glucose Tipo 2/genética , Hipotálamo/metabolismo , Camundongos , Nicotina/administração & dosagem , Agonistas Nicotínicos/administração & dosagem , Pâncreas/metabolismo , Proteínas Circadianas Period/efeitos dos fármacos , Proteínas Circadianas Period/genética
2.
Vet Med Sci ; 5(3): 451-461, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-30973212

RESUMO

The ban on the use of antibiotic in feed encouraged nutritionists to using alternatives to maintain growth performance and intestinal function of broilers. This study was conducted to evaluate the effects of Yupingfeng polysaccharides (YP) supplementation on growth performance and expression of SGLT1, GLUT2 and GLUT5 in Qingyuan partridge chicken. Experiment 1: a total of 540 chickens were randomly allocated to five groups with six replication. Dietary treatments were: (1) CON (control group), basal diet; (2) T1, CON + 0.5 g kg-1 YP; (3) T2, CON + 1 g kg-1 YP; (4) T3, CON + 2 g kg-1 YP; (5) T4, CON + 4 g kg-1 YP. Experiment 2, a total of 162 were randomly allocated to three groups with three replication. Dietary treatments were: (1) CON, basal diet; (2) T1, CON + 0.5 g kg-1 YP; (3) T2, CON + 1 g kg-1 YP. From days 1 to 14 and overall, chicken fed T1 diet had higher ADG. On day 42, there was increased villus height of jejunum in T1 group. On days 14 and 28, there was decreased villus height of duodenum and jejunum in T2 group. In duodenum, the expression of SGLT1 (days 21, 35 and 42), GLUT2 (days 7, 14, 21, 28, 35 and 42) and GLUT5 (days 7, 14, 21 and 28) was increased with YP supplementation. In jejunum, the expression of SGLT1 (days 7, 14, 21, 28 and 35), GLUT2 (days 14, 21, 28, 35 and 42) and GLUT5 (days 7, 14, 21, 28, 35 and 42) was increased with YP supplementation. In ileum, the expression of SGLT1 (days 7, 21, 35 and 42), GLUT2 (days 7, 14, 21 and 42) and GLUT5 (days 7, 14, 21, 28, 35 and 42) was increased with YP supplementation. Dietary YP supplementation improves growth performance and expression of SGLT1, GLUT2 and GLUT5 in intestine.


Assuntos
Galinhas/crescimento & desenvolvimento , Suplementos Nutricionais/análise , Medicamentos de Ervas Chinesas/farmacologia , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Polissacarídeos/farmacologia , Ração Animal/análise , Animais , Galinhas/anatomia & histologia , Galinhas/genética , Dieta/veterinária , Regulação da Expressão Gênica no Desenvolvimento/genética , Transportador de Glucose Tipo 2/efeitos dos fármacos , Transportador de Glucose Tipo 2/genética , Transportador de Glucose Tipo 5/efeitos dos fármacos , Transportador de Glucose Tipo 5/genética , Mucosa Intestinal/anatomia & histologia , Mucosa Intestinal/efeitos dos fármacos , Intestino Delgado/anatomia & histologia , Intestino Delgado/efeitos dos fármacos , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/genética , Distribuição Aleatória , Transportador 1 de Glucose-Sódio/efeitos dos fármacos , Transportador 1 de Glucose-Sódio/genética , Regulação para Cima
3.
Stress ; 20(6): 562-572, 2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-28911262

RESUMO

High ambient temperature adversely influences poultry production. In the present study, gamma amino butyric acid (GABA) supplementation was used to alleviate the adverse changes due to heat stress (HS) in a broiler chicken strain (Ross 308). At 21 days of age, the birds were divided into four groups of 13. Two groups were housed under normal room temperature, one group was given orally 0.2 ml 0.9% physiological saline (CN) daily, the other group received 0.2 ml of 0.5% GABA solution orally (GN). A third group was exposed to environmental HS (33 ± 1 °C lasting for 2 weeks) + physiological saline (CH) and a fourth group was exposed to HS + GABA supplementation (GH). GABA supplementation during HS significantly reduced the birds' increased body temperature (p <.0001) and increased their body weight gain (p <.0001). This effect was associated with increases in the heat stress-induced reductions in jejunal villus length, crypt depth and mucous membrane thickness, and decreases in the vascular changes occurred due to HS. Additionally, GABA supplementation significantly modulated HS-induced changes in glucose facilitated transporter 2 (GLUT2), peptide transporter 1 (PEPT1) and heat shock protein 70 (HSP70) mRNA expression in the jejunal mucosa (p < .0001). GABA supplementation also significantly elevated the triiodothyronine (T3) hormone level and hemoglobin levels and decreased the heterophil-lymphocyte ratio (H/L ratio) (p <.0001). Furthermore, it induced higher hepatic glutathione peroxidase enzyme (GSH-Px) activities and decreased the malondialdehyde dehydrogenase (MDA) content. These results indicate that GABA supplementation during HS may be used to alleviate HS-related changes in broiler chickens.


Assuntos
GABAérgicos/farmacologia , Transportador de Glucose Tipo 2/efeitos dos fármacos , Proteínas de Choque Térmico HSP70/efeitos dos fármacos , Resposta ao Choque Térmico/efeitos dos fármacos , Temperatura Alta/efeitos adversos , Mucosa Intestinal/efeitos dos fármacos , Jejuno/efeitos dos fármacos , Transportador 1 de Peptídeos/efeitos dos fármacos , RNA Mensageiro/efeitos dos fármacos , Ácido gama-Aminobutírico/farmacologia , Animais , Galinhas , Transportador de Glucose Tipo 2/genética , Transportador de Glucose Tipo 2/metabolismo , Glutationa Peroxidase/efeitos dos fármacos , Glutationa Peroxidase/metabolismo , Proteínas de Choque Térmico HSP70/genética , Proteínas de Choque Térmico HSP70/metabolismo , Transtornos de Estresse por Calor , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia , Jejuno/metabolismo , Jejuno/patologia , Fígado/efeitos dos fármacos , Masculino , Malondialdeído/metabolismo , Oxirredutases/efeitos dos fármacos , Oxirredutases/metabolismo , Transportador 1 de Peptídeos/genética , Transportador 1 de Peptídeos/metabolismo , RNA Mensageiro/metabolismo , Estresse Fisiológico/efeitos dos fármacos
4.
J Agric Food Chem ; 63(51): 10903-13, 2015 Dec 30.
Artigo em Inglês | MEDLINE | ID: mdl-26592089

RESUMO

Cichoric acid, a caffeic acid derivative found in Echinacea purpurea, basil, and chicory, has been reported to have bioactive effects, such as anti-inflammatory, antioxidant, and preventing insulin resistance. In this study, to explore the effects of CA on regulating insulin resistance and chronic inflammatory responses, the insulin resistance model was constructed by glucosamine in HepG2 cells. CA stimulated glucosamine-mediated glucose uptake by stimulating translocation of the glucose transporter 2. Moreover, the production of reactive oxygen, the expression of COX-2 and iNOS, and the mRNA levels of TNF-α and IL-6 were attenuated. Furthermore, CA was verified to promote glucosamine-mediated glucose uptake and inhibited inflammation through PI3K/Akt, NF-κB, and MAPK signaling pathways in HepG2 cells. These results implied that CA could increase glucose uptake, improve insulin resistance, and attenuate glucosamine-induced inflammation, suggesting that CA is a potential natural nutraceutical with antidiabetic properties and anti-inflammatory effects.


Assuntos
Anti-Inflamatórios , Ácidos Cafeicos/farmacologia , Glucosamina/farmacologia , Hipoglicemiantes , Inflamação/prevenção & controle , Resistência à Insulina , Succinatos/farmacologia , Suplementos Nutricionais , Glucose/metabolismo , Transportador de Glucose Tipo 2/efeitos dos fármacos , Transportador de Glucose Tipo 2/metabolismo , Células Hep G2 , Humanos , Inflamação/induzido quimicamente , Fígado/efeitos dos fármacos , Fígado/metabolismo , Transdução de Sinais/efeitos dos fármacos
5.
Int J Biol Sci ; 11(5): 508-24, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25892959

RESUMO

Diabetes mellitus (DM) is a metabolic diseases characterized by hyperglycemia due to insufficient or inefficient insulin secretory response. This chronic disease is a global problem and there is a need for greater emphasis on therapeutic strategies in the health system. Phytochemicals such as flavonoids have recently attracted attention as source materials for the development of new antidiabetic drugs or alternative therapy for the management of diabetes and its related complications. The antidiabetic potential of flavonoids are mainly through their modulatory effects on glucose transporter by enhancing GLUT-2 expression in pancreatic ß cells and increasing expression and promoting translocation of GLUT-4 via PI3K/AKT, CAP/Cb1/TC10 and AMPK pathways. This review highlights the recent findings on beneficial effects of flavonoids in the management of diabetes with particular emphasis on the investigations that explore the role of these compounds in modulating glucose transporter proteins at cellular and molecular level.


Assuntos
Diabetes Mellitus Tipo 2/metabolismo , Dieta/veterinária , Flavonoides/farmacologia , Transportador de Glucose Tipo 2/metabolismo , Transportador de Glucose Tipo 4/metabolismo , Diabetes Mellitus Tipo 2/tratamento farmacológico , Suplementos Nutricionais , Flavonoides/química , Transportador de Glucose Tipo 2/efeitos dos fármacos , Transportador de Glucose Tipo 4/efeitos dos fármacos , Humanos , Hipoglicemiantes/química , Hipoglicemiantes/farmacologia , Compostos Fitoquímicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA